LEXXW Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: ACCESS Newswire - Mentions: LEXX

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

2 months ago - By: ACCESS Newswire - Mentions: LEXX

Lexaria Bioscience Corp. Provides Strategic Update

2 months ago - By: ACCESS Newswire - Mentions: LEXX

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2 months ago - By: ACCESS Newswire - Mentions: LEXX

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

3 months ago - By: ACCESS Newswire - Mentions: LEXX

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

4 months ago - By: ACCESS Newswire - Mentions: LEXX

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

4 months ago - By: ACCESS Newswire - Mentions: LEXX

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

5 months ago - By: ACCESS Newswire - Mentions: LEXX

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

3 months ago - By: ACCESS Newswire - Mentions: LEXX

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

4 months ago - By: ACCESS Newswire - Mentions: LEXX

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

6 months ago - By: ACCESS Newswire - Mentions: LEXX

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

6 months ago - By: ACCESS Newswire - Mentions: LEXX

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

6 months ago - By: ACCESS Newswire - Mentions: LEXX

Lexaria Attending BIO International Convention

7 months ago - By: ACCESS Newswire - Mentions: LEXX

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

8 months ago - By: ACCESS Newswire - Mentions: LEXX

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology

8 months ago - By: ACCESS Newswire - Mentions: LEXX

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

8 months ago - By: ACCESS Newswire - Mentions: LEXX

Lexaria's Human GLP-1 Study #5 Begins Dosing

10 months ago - By: ACCESS Newswire - Mentions: LEXX

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

7 months ago - By: ACCESS Newswire - Mentions: LEXX

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

8 months ago - By: ACCESS Newswire - Mentions: LEXX

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

9 months ago - By: ACCESS Newswire - Mentions: LEXX

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)

10 months ago - By: ACCESS Newswire - Mentions: LEXX

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

10 months ago - By: ACCESS Newswire - Mentions: LEXX

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

10 months ago - By: ACCESS Newswire - Mentions: LEXX

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

10 months ago - By: ACCESS Newswire - Mentions: LEXX

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

10 months ago - By: ACCESS Newswire - Mentions: LEXX

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

10 months ago - By: ACCESS Newswire - Mentions: LEXX

LEXARIA BIOSCIENCE -CW25 (LEXXW) Stock News

LEXXW Latest News, Press Relases and Analysis

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Bioscience Corp. Provides Strategic Update

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Lexaria Attending BIO International Convention

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Lexaria's Human GLP-1 Study #5 Begins Dosing

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Lexaria Releases Annual Letter from the CEO